Slide 1: Nanexa AB Company Presentation
Nanexa AB Company Presentation September 2026 Redefining Injectables. One Layer at a Time. nanexa.com
Slide 2: About Nanexa
About Nanexa September 2026 2 A pharmaceutical company developing long-acting injectables with its proprietary PharmaShell® platform The Company The Technology The Business Model Founded in 2007, with a pharmaceutical focus PharmaShell® coats drug particles with an Internal NEX programs across pepti
Slide 3: Novo and Moderna – Two Global License Transactions Signed in the Past Twelve Months
Novo and Moderna – Two Global License Transactions Signed September 2026 3 in the Past Twelve Months Global license and Global license and option Other active partnerships collaboration Agreement Agreement with Moderna – with Novo – September 2026 December 2025 Joint Development Agreement with Forge
Slide 4: Comparison of Long-Acting Injectable (LAI) Technologies
Comparison of Long-Acting Injectable (LAI) Technologies September 2026 4 PharmaShell® offers several competitive advantages over other technologies, including higher drug, longer dosing intervals, and no API modification Polymer depots Lipid depots Prodrugs PharmaShell ® Companies offering MedInCell
Slide 5: PharmaShell Combines Broad Applicability with Patient and Manufacturing Advantages
PharmaShell® Combines Broad Applicability with Patient and September 2026 5 Manufacturing Advantages Broad API applicability Patient advantages • Does not modify the API or its functionality • Less frequent dosing; once-monthly or once- quarterly • Gentle process, suited to sensitive biologics such
Slide 6: PharmaShell Utilizes Atomic Layer Deposition to Tailor Depot Durations
September 2026 6 PharmaShell® Utilizes Atomic Layer Deposition to Tailor Depot Durations • Atomic Layer Deposition (ALD) is a gas-phase technique creating Nanoscale coating extremely thin surface coatings • The coating is grown layer by layer from inorganic oxides on every drug particle Particle of
Slide 7: PharmaShell Controls Drug Release from the Depot
PharmaShell® Controls Drug Release from the Depot September 2026 7 1) PharmaShell® coated particles 2) The coating on the particles 3) The drug is released into are injected as a liquid facing the surrounding tissue systemic circulation as the suspension and form a depot dissolves first. This proces
Slide 8: PharmaShell is Validated Through Multiple Preclinical and Clinical Studies Across Various Modalities
September 2026 8 PharmaShell® is Validated Through Multiple Preclinical and Clinical Studies Across Various Modalities • Weekly and monthly depots of small molecules and peptides confirmed in Phase 1 NEX studies • NEX-18 : Oncology – azacitidine in Myelodysplastic Syndrome (MDS) • NEX-20 : Oncology
Slide 9: Accumulated PharmaShell Data Drives a Predictive Development Loop
September 2026 9 Accumulated PharmaShell® Data Drives a Predictive Development Loop: from in vitro, to animals, to human Design NEX-22 Clinical data aligns closely with profiles observed in vitro and in rat PK studies Coating thickness and composition targeting a specific release rate Normalized cum
Slide 10: NEX-18 and NEX-20 Validate Extended Release Across Two Small-Molecule Programs
September 2026 10 NEX-18 and NEX-20 Validate Extended Release Across Two Small-Molecule Programs NEX-18 azacitidine NEX-20 lenalidomide Plasma Plasma Plasma exposure, concentration 1000 concentration 1000 AUC 5000 (ng/mL) (ng/mL) (h*ng/mL) 100 100 3750 10 10 2500 1 1 1250 0.1 0.1 0 0 1 2 3 4 5 6 0 7
Slide 11: NEX-22 Phase 1 Data Shows Positive Proof of Concept for a Once-Monthly GLP-1 analogue
September 2026 11 NEX-22 Phase 1 Data Shows Positive Proof of Concept for a Once-Monthly GLP-1 analogue Liraglutide plasma conc 100 100 First three days 30 mg • Extended release over 36 days (nmol/L) 10 10 mg of liraglutide after a single 1 4.5 mg subcutaneous injection in 10 0.1 0 1 2 3 1.5 mg part
Slide 12: Phase 1 Learnings Deliver Monthly and Quarterly Dosing of GLP-1 therapy
September 2026 12 Phase 1 Learnings Deliver Monthly and Quarterly Dosing of GLP-1 therapy PK in rat of two new and improved Simulation of repeated dosing in PharmaShell® offers a narrower peak- PharmaShell® formulations with semaglutide humans combining observed to-trough ratio when dosed monthly gu
Slide 13: PharmaShell Coating Process Preserves Antibody Integrity and Binding
PharmaShell® Coating Process Preserves Antibody September 2026 13 Integrity and Binding • Even with highly sensitive APIs such as No significant change in the activity of the mAb after PharmaShell® coating monoclonal Antibodies (mAbs), the PharmaShell® process does not change API ns activity 100% •
Slide 14: In-House GMP Manufacturing Since 2020 and a Forge Nano Partnership for Large-Scale ALD Equipment
In-House GMP Manufacturing Since 2020 and a Forge Nano September 2026 14 Partnership for Large-Scale ALD Equipment GMP manufacturing established at Nanexa site Collaboration with Forge Nano for large-scale equipment • GMP-certified operations in Uppsala since 2020 • Joint Development Agreement (Sept
Slide 15: A Diversified Pipeline Proves PharmaShell Applies Across Modalities and Markets
A Diversified Pipeline Proves PharmaShell® Applies September 2026 15 Across Modalities and Markets Formulation and Preclinical Phase 1 Phase 2 and beyond NEX-18 & NEX-20 – oncology Small molecules Undisclosed partner project weekly & monthly Semaglutide – monthly & quarterly NEX-22 – GLP-1 liragluti
Slide 16: Where PharmaShell Can Create the Most Value
Where PharmaShell® Can Create the Most Value September 2026 16 The highest-value opportunities combine a meaningful dosing burden with APIs that benefit from high drug load, controlled release and an unmodified API molecule Frequent or high dosing burden High dose in a low volume injection Existing
Slide 17: The most exciting part of our journey still lies ahead
From innovation to validation. September 2026 17 From potential to opportunity. “The most exciting part of our journey still lies ahead” David Westberg Chief Executive Officer, Nanexa AB (publ) nanexa.com
Slide 18: A Management Team with Drug Development Experience Taking Drugs from Early Research to Market
A Management Team with Drug Development Experience September 2026 18 Taking Drugs from Early Research to Market David Westberg Anders Johansson CEO Co-founder and head of IP/Patent Edu. MSc KTH Royal Institute of Technology Edu. PhD University of Uppsala Cecilia Danckwardt-Lillieström Mikael Asp CFO
Slide 19: A Board with Deep Pharmaceutical, Business and Capital Market Experience
A Board with Deep Pharmaceutical, Business and Capital September 2026 19 Market Experience Göran Ando Hanna Tilus Chairman of the Board Board director Edu. Master of Laws, LL.M. and Bachelor´s degree Edu. MD University of Linköping Psychology, Stockholm University Richard Davis Jakob Dynnes Hansen B
Slide 20: A Broad Patent Portfolio Protects the PharmaShell Opportunity at Least Through 2046
A Broad Patent Portfolio Protects the PharmaShell® September 2026 20 Opportunity at Least Through 2046 14 patent families, with granted patents and/or pending patent applications in or in respect of up to 50 countries, having normal expiry dates extending up to 2046 New inventions patented by Nanexa
Slide 21: nanexa.com
1 ORs nanexa.com